arrow
Y

Yuk Ting

University of Birmingham
H指数:25
被引数:6,675

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine

ABC-12:探索度伐利尤单抗(MEDI4736)联合顺铂/吉西他滨一线治疗晚期胆道癌患者中的微生物组

2025-07-290
PRE
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial
2023-12-017
OAAI
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX , or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

吉西他滨联合卡培他滨、FOLFIRINOX或放化疗治疗边缘可切除胰腺癌患者的即刻手术比较 (ESPAC5): 一项四组、多中心、随机、2期临床试验

2023-02-01143
OAAI
Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
2022-06-010
OA
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
2022-04-1442
OA
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2021-06-0227
OAAI
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
2020-08-152
PRE
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
2020-04-3013
OAAI
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
2019-11-01171
OAAI
New vaccination strategies in liver cancer (vol 36, pg 125, 2017)
2019-04-010
PREAI
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
2018-10-0160
OA